60%+ returns in 2025: Here’s how AI-powered stock investing has changed the game
Idexx Laboratories Inc. stock reached an all-time high of 735.31 USD, marking a significant milestone for the company. According to InvestingPro data, the stock is trading just 1% from its 52-week high, with analysts setting price targets as high as $830. Over the past year, the stock has experienced a remarkable 75.02% increase, reflecting strong investor confidence and robust company performance. InvestingPro data shows a slightly more conservative but still impressive 64.7% one-year return, with a substantial 37.6% gain in just the past six months. This new peak underscores the company’s sustained growth trajectory and market leadership in the veterinary diagnostics sector, supported by a strong 10% five-year revenue CAGR. Investors have been encouraged by Idexx’s consistent revenue growth and innovative product offerings, which have bolstered its market position and contributed to its impressive stock performance over the past year. The company maintains a healthy 61.7% gross profit margin and impressive 65% return on equity, though InvestingPro analysis indicates the stock is currently trading above its Fair Value. Four analysts have recently revised earnings upward for the upcoming period, suggesting continued confidence in Idexx’s $58.2 billion market cap business. For deeper insights into IDXX and 1,400+ other stocks, including comprehensive Pro Research Reports, consider an InvestingPro subscription.
In other recent news, IDEXX Laboratories reported a strong performance for the third quarter of 2025, surpassing both earnings and revenue expectations. The company achieved earnings per share of $3.22, beating the forecast of $3.14, and reported revenue of $1.1 billion, exceeding the anticipated $1.07 billion. Following these results, Jefferies and BTIG both raised their price targets for IDEXX Laboratories to $830, maintaining a Buy rating. Jefferies highlighted a 13% sales growth and a 16% increase in EBITDA as factors contributing to the raised guidance. Stifel also increased its price target to $775, citing a positive growth outlook and maintaining its Buy rating. The firm noted the potential for growth in consumables, particularly from the Pancreatic Lipase product. IDEXX’s strong quarterly results and optimistic future projections have drawn positive attention from multiple analyst firms. These developments reflect an overall positive sentiment towards IDEXX Laboratories in the investment community.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.